Finding vulnerable atherosclerotic plaques: is it worth the effort?

Area of Science:

• Cardiovascular research
• Medical imaging technologies
• Plaque characterization

Background:

• Most deaths from cardiovascular disease are attributed to thrombotic occlusion of a single vulnerable plaque.
• While multifocal disease is common, the significance of identifying multiple vulnerable plaques remains a research focus.
• Risk factors poorly predict angiographic progression and are weak predictors of myocardial infarction (MI) or death.

Purpose of the Study:

• To review current research on identifying and treating vulnerable plaques.
• To evaluate the utility of various imaging modalities in detecting multiple vulnerable plaques.
• To discuss the implications of these findings for patient risk stratification and therapeutic strategies.

Main Methods:

• Review of intravascular ultrasonography (IVUS) studies in patients with stable angina, unstable angina, and acute myocardial infarction (MI).
• Analysis of angioscopy findings regarding the incidence of second vulnerable plaques.
• Evaluation of thermography catheter data for detecting "hot lesions" indicative of vulnerable plaques.
• Discussion of emerging imaging techniques and predictive models for plaque risk assessment.

Main Results:

• IVUS identifies plaque rupture in most MI patients and approximately half of unstable angina patients, detecting a second vulnerable plaque in many unstable angina and most MI patients.
• Angioscopy shows a lower incidence of second vulnerable plaques but identifies additional yellow plaques in many patients across angina categories.
• Thermography reveals multiple "hot lesions" in a significant portion of stable angina patients, depending on the temperature cutoff used.

Conclusions:

• New imaging techniques and predictive models offer enhanced detection of vulnerable plaques and patient risk assessment.
• Identifying multiple vulnerable plaques is clinically relevant, particularly in acute myocardial infarction.
• These advancements may enable physicians to "buy time" with local therapies while systemic treatments stabilize plaques, potentially reducing risk in non-responders.